TrialInvestigational new drugs2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
J Nehra et al.PubMed ↗Publisher ↗
No numbers read from the abstract.